Abbott milk powder

 

Abbott milk powder edit entry B add meaning? As a global leader in nutrition products with 120 years of medical background, Abbott has always made milk powder with a rigorous pharmaceutical attitude, and has won the trust of doctors and mothers in nearly 100 countries and regions with its scientific and perfect formula. All products sold by Abbott in China are imported with original packaging, and are produced and packaged abroad. For the quality and safety of imported products, AQSIQ strictly controls and checks them according to the Law of the People's Republic of China on Import and Export Commodity Inspection and the relevant provisions on the administration of imported food inspection and quarantine. Each batch of Abbott's imported products have passed the inspection and quarantine at the port and obtained the health inspection certificate.

Company profile

AbbottLaboratories was founded in 1888 in Chicago by Dr. Abbott. Abbott is one of the world's leading diversified pharmaceutical and healthcare products companies, focusing on two areas of original research and development pharmaceutical and medical products.

After 100 years of development, Abbott has developed into a Fortune 500 company with diversified pharmaceutical and nutrition products. After more than half a century of development, the infant nutrition products of "Xinmeili" infant milk powder, which was first developed and launched on the market in 1927, have been constantly improving and advanced. In 1998, "Xikangbao" infant milk powder was the first to add 72 mg/l TPAN nucleotide, creating a new era of infant nutrition. At present, all of Abbott's nutritional products: pregnant women's milk powder, newborn baby milk powder, 1 to 3 years old milk powder, etc., have entered the Meizhou market and are sold in major supermarkets. Abbott's healthcare products and services include pharmaceuticals, nutrition products, hospital supplies and diagnostic supplies. Abbott employs more than 57,000 people in 44 countries in manufacturing, distribution and associate operations. Abbott products serve patients in 130 countries around the world.

Abbott is the largest market leader in pediatric nutrition in the United States, with a wide range of activities supporting health care professionals who advise parents on child nutrition issues. Among Abbott's fast-growing businesses are medical nutrition products. These products can be fed orally or tube-fed and are suitable for providing comprehensive or supplementary nutrition to people with special nutritional needs. Abbott is a major manufacturer of medical nutrition products and tube feeding equipment in the United States, and is actively expanding the international market for these products.

Abbott is one of the world's leading diversified pharmaceutical and healthcare products companies, with more than 7,000 Abbott scientists engaged in research and development around the world.

The original R&D pharmaceutical business ranks among the top 10 in the world. World-renowned products include erythromycin, the antibiotic Claxin for the treatment of helicobacter pylori, the anesthetic sevoflurane and the AIDS drug Agarb, among others.

The infant nutrition business ranks among the top three in the world and one in the United States. Infant formula products were introduced as early as 1927. The taurine formula was introduced in the 1960s, and the TPAN nucleotide patent was obtained in the 1980s.

Medical nutrition products ranked one in the world. Medical supplements are available for people with special nutritional needs such as diabetes, wasting due to cancer, and kidney and respiratory diseases, and for patients requiring energy supplements or tube feeding.

The medical products business also includes diagnostic products, diabetes care products, molecular medicine products, in-hospital rapid diagnostic products, vascular products, spinal products, veterinary drugs and other product categories. Abbott Diagnostics invented one of the world's AIDS diagnostic kits.

Abbott has a long history of good relationships with numerous medical and health authorities in the People's Republic of China. From the early 1980s to the present, Abbott has been conducting academic exchanges, product introductions and business contacts in various provinces and cities in China. As the modernization of China's medical industry continues to accelerate, Abbott's cooperation with the medical industry in the People's Republic of China will have a broader prospect.

Basic information

2011 Fortune Global 500 Ranking: No. 255 (Previous year's ranking :250)

Company headquarters City address: Abbott Technology Park (AbbottPark)

Chief Executive Officer: MilesD.White

Country: United States of America

Number of employees: 91,440

Development course

Abbott was founded in 1888 by a Chicago pharmacist named Dr.WallaceCalvinAbbott. As the company has grown, its business has grown from a simple pharmaceutical business to a business that now includes the research, production and sale of medicines and a range of services from disease prevention, diagnosis and treatment. Headquartered in North Chicago, Abbott sells in more than 130 countries. For more than a century, Abbott has made significant contributions to the health of people around the world.

Abbott is a leader in the field of medicine, nutrition and medical device manufacturing. The company is committed to: diabetes, pain, respiratory infections, HIV/ AIDS, men's and women's health, maternal and child health, veterinary diseases and other research areas. Abbott has more than 7,000 scientists worldwide engaged in the field of medical research. The company spends more than $1 billion a year on research.

Abbott is in China

Abbott set up offices in Beijing and Shanghai in 1995 as a subsidiary of Swiss Abbott, followed by additional offices in Guangzhou and Shenzhen. In 1998, Shanghai Abbott Pharmaceutical Co., Ltd. was established as a joint venture with Shanghai Meiyou Pharmaceutical Co., LTD. The factory is located in Fengxian, Shanghai, and passed GMP certification in 2000. Abbott Trading (Shanghai) Co., Ltd. was established in Shanghai Waigaoqiao Free Trade Zone in 2001. At present, Abbott has more than 1,200 employees in China, which are engaged in the marketing of pharmaceuticals, nutritional products, medical diagnostics and devices. China headquarters is located in Shanghai.

Financial summary

In 2006, Abbott reported sales and profits from continuing operations of $22.9 billion and $3.4 billion, respectively. Abbott also reported its 328th consecutive quarterly dividend paid to shareholders since 1924. 2005 marked the 33rd year in which Abbott's dividend has increased. The company's Medical Products business, which generated sales of more than $8 billion, includes diagnostics, nutrition, diabetes care, molecular diagnostics, intensive care devices, cardiovascular products, spinal products, and animal health. Abbott's pharmaceutical business generated sales of more than $13 billion, including its pharmaceutical facilities in the United States and abroad.

Abbott has leading positions in multiple multi-billion dollar businesses with access to unique revenue and growth balanced opportunities and cash flow sources that enable the company to invest in the future. In 2006, Abbott invested more than $2.3 billion in research and development to further strengthen its dynamism and sustain its success. During 2006, Abbott's operating cash flow from continuing operations was $5.3 billion.

Main product

Originally developed pharmaceutical products

Abbott Laboratories aims to create a world-class pharmaceutical company dedicated to discovering, developing and marketing breakthrough medicines to improve patient health. The focus of the group's work is to translate innovative technologies into effective medicines to address unmet medical needs.

Medical product

Abbott Medical Products has established significant businesses in diagnostic testing equipment, medical devices and nutritional products for children and adults. The group is committed to developing highly differentiated and innovative products for patients and consumers.

Ethics and integrity

At Abbott, we are committed to maintaining the trust of our stakeholders. A commitment to compliance with the law is crucial because health care is one of the most tightly regulated industries. Maintaining that trust, however, requires continuous improvement of Abbott's culture that encourages ethical behavior and compliance with the law. The Ethics and Conduct Office provides employees with resources on many ethics and conduct issues, including the Abbott Code of Business Conduct, the Ethics and Conduct helpline, departmental ethics staff, and an extensive in-person and web-based training program.

Receive honor

According to major media reports, Abbott is ranked among the top companies in the world, both in terms of financial strength and workplace characteristics. These media include:

Fortune is ranked No. 5 on its list of "envied companies" in the pharmaceutical industry. The Fortune 500 ranks 254th in the world. (Ranked by income in 2007)

Ranked in the top 10 of DiversityInc's "Top 50 Diverse Companies."

It was ranked 149th on the Forbes 2007 list. (Ranked by sales, profits, assets and market value)

Working Woman is listed in the "100 Best Companies for Working Women."

In Science's ranking of the world's respected biotechnology and pharmaceutical companies, Abbott is among the top 20 companies for scientists.

The Scientist is listed as one of the best industry Places to Work for Scientists.

Enterprise ranking

Abbott ranked fifth on the "Top 50 Companies for Diversity" list

Through its leadership efforts, diversity training of employees, and the integration of networking organizations like WomenLeadersinAction(WLA) into a connected internal group, Abbott, a company founded and led by women, has fostered an inclusive culture. Thus selected DiversityInc magazine's annual "diversified enterprise 50 strong" (Top50CompaniesforDiversity), and finished fifth.

To earn this honor, Abbott has been committed to creating an inclusive environment and culture where all of its employees, regardless of gender, cultural background and personal beliefs, feel comfortable. As a global leader in healthcare and one of the largest employers in the Chicago area, Abbott is one of only two pharmaceutical companies to make the list. The full list will be published in the magazine's June issue.

Diversity and inclusion are particularly important to Abbott. The hiring and promotion of talented people and a diverse employee base is a priority strategy. Women make up 39 per cent of Abbott's management staff, while 17 per cent of managers are minorities. This long-term commitment to workplace diversity ensures that our employees represent and have diverse experiences, perspectives, cultures, and backgrounds, thus helping us address some of today's complex diseases and medical issues.

Abbott laboratories in special ranking DiversityInc dangerous "for women in senior management personnel of the enterprise" (BestCompaniesforExecutiveWomen), "Hiring and keeping women and minority talents of enterprises" (BestCompaniesforRecruitmentandRetentionforWomenandMinorities) third, "hire and keep good Asian talent enterprise" the sixth place, And seventh place for "Best Companies to Hire and Retain Latino Talent."

In the past nine months, Abbott Laboratories has spent $10.1 billion on acquisitions, including $3.7 billion on Kos, a maker of cholesterol drugs. This year, many analysts thought Abbott Chairman and CEO Miles White needed to take a little breath so the company could absorb its new assets or reduce its $7 billion debt load. But they were wrong.

After completing the Kos acquisition, Abbott announced on January 18th that it would sell two-thirds of its $4 billion diagnostics business to General Electric for $8.1 billion in cash. White has repeatedly said he is in no rush to make deals, but may use the money to buy more drugmakers to keep sales and profits up by at least 10% a year for the next decade. "You can never rest," Mr. White said of mergers and acquisitions. White, 51, who ran Abbott's diagnostics business before he was promoted to CEO in 1999, has been busy making acquisitions ever since. His first big move was to buy Knoll Pharmaceuticals, a division of Germany's BASF, for $7.2 billion in 2001. Among other acquisitions, White bought Alameda, California-based TheraSense Inc., which makes blood-sugar monitoring devices, for $1.2 billion in cash in 2004. At a time when many big pharma companies are ruing their acquisition-for-growth strategy, analysts say Abbott has done well.

The acquisition of Knoll, for example, led to the launch of Humira, a rheumatoid arthritis drug that had sales of $2 billion in 2006. And its $4.1 billion acquisition of Guidant's stent division earlier in 2006 brought its Xience drug-coated stents. If it passes clinical trials, it will enter the U.S. market by the end of the year and is expected to have sales of $1.5 billion in 2008. "Overall, they are pretty savvy acquirers," said Philippe Narbonne of RBC Capital Markets. He also said Abbott didn't overbid and was adept at integrating employees and divisions of acquired companies, often bringing in line managers from acquired companies to train Abbott employees. Mr White's deals have boosted Abbott's revenues and profits.

Glenn Novaro, an analyst at Bank of America Securities in New York, points out that Abbott made $3.8 billion on sales of $22.5 billion in 2006, with a gross margin of nearly 59%. In 1999, Abbott's gross profit was 54.4%, sales were 13.2 billion US dollars, and net profit was 2.4 billion US dollars. It can be seen that Abbott has grown at an average annual rate of 10% in recent years. Its sales and earnings are growing at a level that puts Merck, Bristol-Myers Squibb and Eli Lilly in the dust. Abbott is not just an acquirer. The North Chicago-based company spun off its $2.6 billion hospital supply unit in mid-2004 to form what is now Hospira Inc. Like Hospira, the diagnostic products unit sold to General Electric had been seen as slow to grow. What it lacks is the breadth of GE's $16.6 billion health care unit when it comes to making high-priced medical devices for use in hospitals, clinics and high-volume laboratories. Abbott's journey has not been easy.

Since problems at Abbott's main plant were revealed in the 1990s, the US Food and Drug Administration (FDA) has banned Abbott from producing many diagnostic tests. After paying a $225 million fine and related costs, Abbott returned to the market in 2003. In the deal with GE, Abbott retains the molecular and diabetes diagnostics businesses, while GE gets Abbott's clinical and consumer blood tests, which had estimated 2006 sales of $2.5 billion. For White, Abbott's role model is Johnson & Johnson. The latter grew through mergers and acquisitions, and many analysts praise its policy of allowing its subsidiaries to operate freely. J&j also has more stable medical device and consumer products divisions to balance the volatile drugs business. Similarly, 55 percent of Abbott's sales depend on pharmaceuticals, while medical devices and nutritional products account for another 45 percent. The acquisition of the diagnostic products division raised the ratio to an abnormal 65% to 35%. But soon after, Abbott put together a 20-person business development team. They work exclusively with Abbott executives to identify and evaluate companies for acquisition. "We make sure we're prepared so that when we want to move into new areas, we can," Mr. White said. "We're not sitting around."